Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Innovation Pharmaceuticals Inc. (IPIX)
USD0.00
+0.00 (+66.67%)
US OTC Healthcare Biotechnology
Address
301 Edgewater Place 1880
Wakefield, MA, US
Wakefield, MA, US
CEO
Leo Ehrlich
Website
ipharminc.com
IPO
2007-05-04
CIK 1355250 ISIN US45782D1000
Description
Innovation Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company dedicated to the development of small molecule therapies. Its pipeline targets a range of medical areas, including inflammatory diseases, cancer, dermatology, and infectious conditions. The company's lead drug candidate, Brilacidin, is currently in development for treating oral mucositis, inflammatory bowel disease, acute bacterial skin and skin structure infection, and COVID-19. Furthermore, Innovation Pharmaceuticals is advancing Kevetrin, an anti-cancer compound being investigated for ovarian cancer. The company holds a license agreement with Alfasigma S.p.A. and has a collaborative research agreement with Fox Chase Chemical Diversity Center, Inc. Established in 2005 and headquartered in Wakefield, Massachusetts, the firm operated as Cellceutix Corporation until its name change to Innovation Pharmaceuticals Inc. in June 2017.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD0.00
+0.00 (+66.67%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
117.8K
Beta
-0.49
Float Shares
514.10M
Free Float %
99.2%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +33.33% | -50.00% | +300.00% | -42.86% | -42.86% | -60.00% | +300.00% | -97.68% | -99.83% | -99.97% | -99.67% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Price Targets & DCF
Current price
0.00
DCF (Levered)
0.00
+394.3%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-28.45
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
1 / 10
No MOAT
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%-100.0%
-
EPS growth Biotechnology: +29.7%+55.0% ★ Q3'23: +39.3% (vs Q3'22)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-249.7% Q3'23: -646.3% (vs Q3'22)
-
Share dilution Biotechnology: -3.4%+0.4% ★ Q3'23: +2.9% (vs Q3'22)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.26× Q3'23: -0.08× (vs Q3'22)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Owner Earnings
Owner's Earnings (history)
From
To
Owner alignment
Owner's Earnings TTM
-2.07M
OE per share TTM
0.00
Owner's Yield
-995.98%
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
27.9%
Ownership Overview
Ownership breakdown
Ownership breakdown not available.
At a glance
Institutional holders
—
Total invested
—
Insider transactions (90d)
0
Beneficial owners (>5%)
5
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Kips Bay Select LP | 45.03M | 9.92% | — | — | — | — | PN | Delaware | 2022-07-05 | ↗ |
| 2 | Leviston Resources LLC | 15.96M | 4.90% | — | — | — | — | OO | Delaware | 2020-07-15 | ↗ |
| 3 | EIN No.: 04-3313407 | 8.00M | 7.40% | — | 8.00M | — | 8.00M | CO | Massachusetts | 2014-09-04 | ↗ |
| 4 | Mary M. Aruda | 6.27M | 3.66% | — | 6.27M | — | 6.27M | IN | United States | 2019-01-22 | ↗ |
| 5 | Wayne O. Aruda | 6.27M | 3.66% | — | 6.27M | — | 6.27M | IN | United States | 2019-01-22 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
Institutional history not available.
Top institutional holders
Top holders not available.
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Ratio by volume
0.00
Bearish
Buys
0
Sells
1
Shares acquired
—
Shares disposed
11.31M
Cash buys
—
Cash sales
—
Net activity
-11,307,527
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2022-12-30 | EHRLICH LEO | Director | J-Other | D | Class B Common Stock | 11,307,527 | 0.00 | — | 4,333,936 | — | ↗ |
| 2021-10-10 | Schechter Barry A | Director | A-Award | A | Stock Option | 1,000,000 | 0.24 | 240.0K | 1,000,000 | — | ↗ |
| 2021-10-10 | Harness Jane A. | Officer | A-Award | A | Stock Option | 500,000 | 0.24 | 120.0K | 500,000 | — | ↗ |
| 2020-09-11 | Harness Jane A. | Officer | A-Award | A | Stock Option | 172,987 | 0.22 | 38.1K | 172,987 | — | ↗ |
| 2020-03-30 | EHRLICH LEO | Director / Officer / 10% Owner | M-Exempt | D | Stock Option (right to buy) | 909,090 | 0.11 | 100.0K | 4,181,820 | — | ↗ |
| 2020-02-23 | Schechter Barry A | Director | A-Award | A | Class A Common Stock | 500,000 | 0.00 | — | 750,000 | — | ↗ |
| 2019-09-01 | Harness Jane A. | Officer | A-Award | A | Class A Common Stock | 58,394 | 0.00 | — | 207,629 | — | ↗ |
| 2019-09-01 | Bertolino Arthur Peter | Director / Officer | F-InKind | D | Class A Common Stock | 421,611 | 0.13 | 54.8K | 2,059,316 | — | ↗ |
| 2019-01-29 | EHRLICH LEO | Director / Officer / 10% Owner | A-Award | A | Class B Common Stock | 909,090 | 0.00 | — | 909,090 | — | ↗ |
| 2018-10-12 | Harness Jane A. | Officer | F-InKind | D | Class A Common Stock | 9,272 | 0.40 | 3.7K | 159,854 | — | ↗ |
| 2018-10-12 | Bertolino Arthur Peter | Officer | F-InKind | D | Class A Common Stock | 218,946 | 0.40 | 87.6K | 2,480,927 | — | ↗ |
| 2018-09-01 | Harness Jane A. | Officer | A-Award | A | Class A Common Stock | 58,394 | 0.00 | — | 169,126 | — | ↗ |
| 2018-09-01 | Bertolino Arthur Peter | Officer | A-Award | A | Class A Common Stock | 1,066,667 | 0.00 | — | 2,699,873 | — | ↗ |
| 2017-12-22 | Bertolino Arthur Peter | Officer | F-InKind | D | Class A Common Stock | 238,048 | 0.70 | 166.6K | 1,633,206 | — | ↗ |
| 2017-09-01 | Harness Jane A. | Officer | F-InKind | D | Class A Common Stock | 6,056 | 0.71 | 4.3K | 110,732 | — | ↗ |
| 2017-09-01 | Bertolino Arthur Peter | Officer | A-Award | A | Employee Stock Option (right to buy) | 617,839 | 0.71 | 438.7K | 617,839 | — | ↗ |
| 2017-06-30 | EHRLICH LEO | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2017-06-30 | Bertolino Arthur Peter | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-09-01 | Harness Jane A. | Officer | A-Award | A | Employee Stock Option (right to buy) | 172,987 | 1.37 | 237.0K | 172,987 | — | ↗ |
| 2016-08-30 | Harness Jane A. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2016-06-30 | Bertolino Arthur Peter | Officer | A-Award | A | Stock Option | 617,839 | 1.39 | 858.8K | 617,839 | — | ↗ |
| 2016-06-10 | Tobin Mark Robert | Director | A-Award | A | Stock Option | 19,665 | 1.58 | 31.1K | 19,665 | — | ↗ |
| 2016-06-10 | Spektor Zorik | Director | A-Award | A | Stock Option | 19,665 | 1.58 | 31.1K | 19,665 | — | ↗ |
| 2016-06-10 | Schechter Barry A | Director | A-Award | A | Stock Option | 19,665 | 1.58 | 31.1K | 19,665 | — | ↗ |
| 2015-11-30 | Menon Krishna | Director / Officer / 10% Owner | J-Other | D | Common Stock | 6,000,000 | 0.00 | — | 15,048,286 | — | ↗ |
| 2015-04-24 | Tobin Mark Robert | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2015-04-24 | Spektor Zorik | Director | — | D | Common Stock | 0 | 0.00 | — | 25,000 | — | ↗ |
| 2015-04-24 | Schechter Barry A | Director | — | D | Common Stock | 0 | 0.00 | — | 285,000 | — | ↗ |
| 2014-12-30 | EHRLICH LEO | Director / Officer / 10% Owner | G-Gift | D | Class A Common par value $0.0001 | 50,000 | 0.00 | — | 8,585,002 | — | ↗ |
| 2014-08-28 | Menon Krishna | Director / Officer / 10% Owner | J-Other | D | Common Stock | 10,000,000 | 0.00 | — | 21,048,286 | — | ↗ |
| 2012-12-21 | EHRLICH LEO | Director / Officer / 10% Owner | G-Gift | D | Class A Common par value #0.0001 | 110,000 | 0.00 | — | 8,635,002 | — | ↗ |
| 2012-05-19 | EHRLICH LEO | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 2,000,000 | 0.51 | 1.02M | 20,000,000 | — | ↗ |
| 2010-12-29 | Menon Krishna | Director / Officer / 10% Owner | A-Award | A | Stock Option (right to buy) | 6,000,000 | 0.11 | 660.0K | 6,000,000 | — | ↗ |
| 2010-12-29 | EHRLICH LEO | Director / Officer / 10% Owner | A-Award | A | Common | 6,000,000 | 0.11 | 660.0K | 18,000,000 | — | ↗ |
| 2010-07-27 | Menon Krishna | Officer | P-Purchase | D | Common | 1,000,000 | 0.00 | — | 31,048,286 | — | ↗ |
| 2010-07-27 | EHRLICH LEO | Director / Officer / 10% Owner | J-Other | A | Common | 1,000,000 | 0.00 | — | 8,745,002 | — | ↗ |
| 2009-10-10 | Menon Krishna | Officer | J-Other | A | Common | 32,048,286 | 0.00 | — | 32,048,286 | — | ↗ |
| 2008-12-07 | Evans George W. | Director / Officer | — | D | Option | 918,910 | 0.20 | 183.8K | 0 | — | ↗ |
| 2007-12-10 | Menon Krishna | Director / Officer / 10% Owner | — | D | Common | 0 | 0.00 | — | 32,048,286 | — | ↗ |
| 2007-12-10 | Evans George W. | Director / Officer | — | I | Common | 0 | 0.00 | — | 917,908 | — | ↗ |
| 2007-12-10 | EHRLICH LEO | Director / Officer / 10% Owner | — | I | Common | 0 | 0.00 | — | 749,972 | — | ↗ |
| 2007-12-07 | Evans George W. | Director / Officer | — | D | Option | 917,910 | 0.15 | 137.7K | 0 | — | ↗ |
| 2005-09-19 | WILDS DAVID M | Director | J-Other | A | Series B Convertible Preferred Stock | 12,333 | 2.17 | 26.8K | 12,333 | — | ↗ |
| 2005-03-28 | WILDS DAVID M | Director | A-Award | A | Director Stock Option | 80,000 | 3.05 | 244.0K | 80,000 | — | ↗ |
| 2005-03-28 | JACKSON LABAN | Director | A-Award | A | Director Stock Option | 80,000 | 3.05 | 244.0K | 80,000 | — | ↗ |
| 2004-08-04 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 9,983 | 9.02 | 90.0K | 163,612 | — | ↗ |
| 2004-08-03 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 2,820 | 9.02 | 25.4K | 173,595 | — | ↗ |
| 2004-07-26 | WILDS DAVID M | Director | M-Exempt | D | Stock Option | 18,750 | 1.07 | 20.1K | 6,250 | — | ↗ |
| 2004-06-17 | WILDS DAVID M | Director / 10% Owner | C-Conversion | D | Series B Preferred Stock | 8,145 | 2.17 | 17.7K | 57,065 | — | ↗ |
| 2004-06-17 | FIRST AVENUE PARTNERS L P /TN/ | 10% Owner | C-Conversion | D | Series B Preferred Stock | 8,145 | 2.17 | 17.7K | 57,065 | — | ↗ |
| 2004-06-16 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 1,404 | 15.00 | 21.1K | 146,035 | — | ↗ |
| 2004-06-16 | FIRST AVENUE PARTNERS L P /TN/ | 10% Owner | S-Sale | D | Common Stock | 1,404 | 15.00 | 21.1K | 146,096 | — | ↗ |
| 2004-06-09 | WILDS DAVID M | Director / 10% Owner | C-Conversion | D | Series B Preferred Stock | 7,700 | 2.17 | 16.7K | 65,210 | — | ↗ |
| 2004-06-03 | WILDS DAVID M | Director / 10% Owner | C-Conversion | A | Common Stock | 148,450 | 2.17 | 322.1K | 247,269 | — | ↗ |
| 2004-05-27 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 43,464 | 9.02 | 392.0K | 98,819 | — | ↗ |
| 2004-05-26 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 86,186 | 9.03 | 778.4K | 142,283 | — | ↗ |
| 2004-05-06 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 51,964 | 9.02 | 468.6K | 228,469 | — | ↗ |
| 2004-04-27 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 24,805 | 9.01 | 223.5K | 280,433 | — | ↗ |
| 2004-04-26 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 68,937 | 9.02 | 621.7K | 305,238 | — | ↗ |
| 2004-04-22 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 25,079 | 9.00 | 225.7K | 374,175 | — | ↗ |
| 2004-04-21 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 195,661 | 9.00 | 1.76M | 399,254 | — | ↗ |
| 2004-04-20 | WILDS DAVID M | Director / 10% Owner | S-Sale | D | Common Stock | 303,904 | 9.86 | 3.00M | 594,915 | — | ↗ |
| 2004-04-13 | WILDS DAVID M | Director / 10% Owner | C-Conversion | A | Common Stock | 898,819 | 2.17 | 1.95M | 898,819 | — | ↗ |
Executive team
Top executives
Shares Outstanding
518.35M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2015 | Krishna Menon President and Chief Scientific Officer | 465.9K | 250.0K | — | — | — | — | 715.9K | 0.00% | ↗ |
| 2 | 2015 | Leo Ehrlich Chief Executive and Financial Officer | 465.9K | 250.0K | — | — | — | — | 715.9K | 0.00% | ↗ |
| 3 | 2015 | William J Alexander Former Chief Operations Officer | 210.9K | — | — | 83.2K | — | 146.5K | 440.6K | 18.89% | ↗ |
| 4 | 2014 | Krishna Menon President and Chief Scientific Officer | 444.7K | — | — | — | — | — | 444.7K | 0.00% | ↗ |
| 5 | 2014 | Leo Ehrlich Chief Executive and Financial Officer | 444.7K | — | — | — | — | — | 444.7K | 0.00% | ↗ |
| 6 | 2013 | Leo Ehrlich Chief Executive and Financial Officer | 404.3K | — | — | — | — | — | 404.3K | 0.00% | ↗ |
| 7 | 2013 | Krishna Menon President and Chief Scientific Officer | 404.3K | — | — | — | — | — | 404.3K | 0.00% | ↗ |
CEO compensation breakdown
No CEO compensation history available.
Proxy statements
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Leo Ehrlich | Chairman, Chief Executive Officer, Chief Financial Officer, Principal Accounting Officer & Secretary | 515.9K | male |
| Jane Harness | Senior Vice President of Clinical Sciences & Portfolio Management | 275.0K | female |
| Jim Boeheim | Business Advisor | — | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for IPIX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
